Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN 4:00:00 PM EDT
| Market Cap (Intraday) | 126.20B |
| Current PE | 29.20 |
| Forward PE | 25.43 |
| 2yr Forward PE | 23.41 |
| 10-Day MA | $1,149.99 |
| 50-Day MA | $1,130.05 |
| 200-Day MA | $996.90 |
Regeneron Pharmaceuticals, Inc. Stock, NASDAQ:REGN
777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
United States of America
Phone: +1.914.847.7000
Number of Employees: 13450
Description
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.